Research programme: T cell receptor T cell therapies - BlueSphere Bio
Latest Information Update: 10 Jul 2024
At a glance
- Originator BlueSphere Bio
- Developer BlueSphere Bio; National Institutes of Health
- Class Antineoplastics; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Recurrent respiratory papillomatosis